Revvity has launched an imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three imaging systems.
These systems include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, as well as the QuantumTM GX3 microCT. Globally, the Vega ultrasound system has been launched, having originally been launched in North America in 2022.
Dr Alan Fletcher, Senior Vice President of Life Sciences at Revvity, said: “In a time when innovative technologies steer medical advancements, we are committed to delivering versatile, high-throughput solutions that enhance preclinical R&D productivity. Our growing portfolio equips researchers with robust capabilities to illuminate scientific discoveries and can expedite the journey from discovery to cure.
“With these advanced tools at their disposal, researchers can interrogate biology, streamline their workflows, and accelerate the pace of scientific advancement.”
